Gilead submits lymphoma candidate idelalisib for FDA approval

09/12/2013 | American City Business Journals

Gilead Sciences filed an application with the FDA for approval to market its oral drug idelalisib for treatment of patients with indolent non-Hodgkin lymphoma who don't respond to Rituxan and chemotherapy with an alkylating agent. A similar application is being prepared for Europe.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health